Our Team

https://www.zylorion.com/wp-content/uploads/2021/12/peter-silverstone.png

Dr. Peter Silverstone

Chief Executive Officer and Director

Dr. Peter Silverstone

Chief Executive Officer and Director

Dr. Silverstone has a 35-year background in brain and pharmaceutical research. Dr. Silverstone has highly relevant expertise in international drug and IP development, digital mental health, regulatory matters, and has been involved in multiple health related start-up companies. Dr. Silverstone previously served as the Senior Vice President, Medical and Scientific Affairs of Biovail, one of Canada’s largest publicly traded pharmaceutical companies with annual revenue in excess of a billion dollars, prior to its merger with Valeant Pharmaceutical International. Dr. Silverstone is currently the Interim Chair of the Department of Psychiatry at the University of Alberta. Dr. Silverstone received his MD at the University of London and spent three years as a research fellow at the University of Oxford. Dr. Silverstone’s research achievements have won several awards and he has published over 120 peer-reviewed articles. Dr. Silverstone is the author of the The Promise of Psychedelics, available here or wherever you buy your books.

https://www.zylorion.com/wp-content/uploads/2021/12/adam-darbellay.png

Adam Darbellay

Chief Financial Officer

Adam Darbellay, MPAcc, CPA, CA

Chief Financial Officer

Mr. Darbellay has over 20-years experience working with global large cap Forbes 2000 public companies, as well as private start-ups. Mr. Darbellay most recently served as the Chief Financial Officer of a Canadian-based life sciences company focused on research, development, and commercialization of novel cannabinoid-based compounds for medical purposes. Prior to that, Mr. Darbellay worked with Nutrien (NYSE:NTR), the world’s largest integrated producer and provider of crop nutrients and services, overseeing the global Finance Transformation function. Mr. Darbellay brings extensive leadership experience in corporate M&A, strategy, and deep financial expertise.

https://www.zylorion.com/wp-content/uploads/2021/12/rutger-engels.png

Dr. Rutger Engels

Chief Scientific Officer

Dr. Rutger Engels

Chief Scientific Officer

Dr. Engels has a 27-years background working in behavioral and mental health and addictions, and has deep expertise in understanding, predicting, and treating various mental health conditions, as well as addictions. Dr. Engels has a PhD in Medical Sciences from the University of Maastricht, the Netherlands. Dr. Engels held various leadership positions at the Radboud University, Netherlands, including serving as the Vice-Dean for Research, and Director of the Behavioral Science Institute. Dr. Engels was appointed and served as Chairperson of the Executive Board of the Trimbos Institute, the National Institute for Mental Health and Addictions, and from 2018 to 2021, Dr. Engels was Rector Magnificus of the Erasmus University Rotterdam, where he was overall responsible for education, research, and strategy. In the last 15 years, Dr. Engels has led a series of randomized trials on digital mental health interventions in collaboration with both high standing academic institutions and companies in North America.

https://www.zylorion.com/wp-content/uploads/2021/12/tracy-hillier.png

Dr. Tracey Hillier

Chief Clinical Officer

Dr. Tracey Hillier

Chief Clinical Officer

Dr. Hillier is a proud member of the Qalipu Mi’kmaq First Nation and spent 20 years in the Canadian Armed Forces as a physician. During this time Dr. Hillier gained extensive experience in working with patients with PTSD, Depression, Anxiety, and Addictions, the four key areas of clinical focus for Zylorion. Additionally, Dr. Hillier gained expertise in international logistics in the medical field, working in multiple countries in a wide variety of roles.  She trained at a master’s level in clinical trial methodology, and also at the Master’s level in Education. Dr. Hillier has led the development of a complex computerized medical training system, and oversaw its successful implementation, in a world- renowned university. Her most recent role was as Director and Executive Dean, Alberta Institute Wenzhou Medical University, an international collaborative start-up between the University of Alberta and a leading Chinese medical facility.

https://www.zylorion.com/wp-content/uploads/2021/12/louise-duchesne.png

Louise M. Duchesne

Chief Risk Officer

Louise M. Duchesne, CPA, CA

Chief Risk Officer

Ms. Duchesne is co-founder and Managing Director of Lightyear Capital Inc., a privately held full-service, IIROC member, investment dealer. Ms. Duchesne has over 30-years of capital markets, finance, accounting, tax, regulatory compliance, and investment industry experience. Prior to co-founding Lightyear, Ms. Duchesne was the Chief Financial Officer and Director of an independent investment dealer. Ms. Duchesne holds a Bachelor of Commerce from McGill University and a CPA, CA designation.

https://www.zylorion.com/wp-content/uploads/2021/12/scott-phillips.png

Scott Phillips

Chief Operating Officer

Scott Phillips, MBA, CPA, CMA

Chief Operating Officer

Mr. Phillips has over 20-years leadership experience in operations across several different industries. Most recently, Mr. Phillips was Assistant Chair, for the Department of Psychiatry at the University of Alberta where he worked directly with mental health education and service delivery. Prior to that, Mr. Phillips led the logistics network for Canada’s third largest private lab, with a team of over 65 employees and contracts covering Western Canada. Mr. Phillips has led multi million-dollar start-ups with focus on both the domestic and international markets, specifically in the technology and fabrication space. Mr. Phillips gained his MBA from Cornell University and maintains a CPA, CMA designation, as well as a PMP designation. In 2019, Mr. Phillips was named one of the Top 40 under 40 in Edmonton, Alberta.

https://www.zylorion.com/wp-content/uploads/2021/12/scott-clarke.png

Scott Clarke

Corporate Secretary

Scott Clarke, B. Comm (Hons), LLB

Corporate Secretary

Mr. Clarke is a senior partner with Blake, Cassels & Graydon LLP, with 24-years experience focused on mergers and acquisitions, power projects, corporate finance, private equity and governance matters (including ESG). Mr. Clarke’s diverse public and private company client base spans life sciences, technology, power (with a focus on alternative energy), oil and gas services and exploration. Mr. Clarke is recognized as a leading lawyer in the Legal 500 Canada, Chambers Canada: Canada’s Leading Lawyers for Business, the Best Lawyers in Canada, the Canadian Legal Lexpert Directory, and Acritas Stars. Mr. Clarke is also a member of the Securities Advisory Committee of the Alberta Securities Commission.

https://www.zylorion.com/wp-content/uploads/2021/12/matthew-brown.png

Dr. Matthew Brown

Vice President, Data Science

Dr. Matthew Brown

Vice President, Data Science

Dr. Brown is a leading researcher in aspects of mental health and the brain, with publications in journals that are part of the Nature group. Dr. Brown has a strong background in psychopharmacology, project management of clinical studies, brain imaging techniques and computational psychiatry, and using artificial intelligence (“AI”) in mental health. Dr. Brown is an associate of the world leading AI group, the Alberta Machine Intelligence Institute at the University of Alberta. Dr. Brown is the co-founder of Retain Labs Medical Inc., a company focused on technology-based training solutions for health professionals. Dr. Brown is a scientific reviewer for Frontiers in Systems in Neuroscience, Neuroimage and Experimental Brain Research. He received his PhD in neuroscience from the University of Western Ontario and was a research fellow in the Department of Psychiatry and Adjunct Professor in the Department of Computing Science at the University of Alberta.

https://www.zylorion.com/wp-content/uploads/2021/12/james-scott.png

Dr. James Scott

Vice President, Mycology

Dr. James Scott

Vice President, Mycology

Dr. Scott is the Founder, Owner, and Chief Scientific Officer of Sporometrics Inc., an independent laboratory and leading provider of basic and applied scientific research on biomedical, industrial, and environmental microbes. Dr. Scott’s PhD in Mycology was earned through the Department of Botany at the University of Toronto in 2001. Dr. Scott’s PhD thesis, ‘Studies on Indoor Fungi’, is still held today as one of the most comprehensive treatments of the mycology of indoor microbes. Dr. Scott is a Professor in Occupational Hygiene with the Dalla Lana School of Public Health at the University of Toronto. Dr. Scott’s many contributions in the field of mycology include research and publications for government agencies, private corporations, and professional bodies, which has established Dr. Scott as a world leader in fungal research and occupational hygiene.

https://www.zylorion.com/wp-content/uploads/2021/12/thijs-boukhoff.png

Thijs Boekhoff

Vice President, Business Development

Thijs Boekhoff

Vice President, Business Development

Mr. Boekhoff is an experienced entrepreneur and international business developer with a demonstrated history of building and growing companies in the healthcare and technology industry in the United States and the European Union. Mr. Boekhoff holds a Master of Business Administration from the Rotterdam School of Management. Mr. Boekhoff has worked and lived in Germany, Amsterdam, Vienna, Rome, Montreal, and San Francisco Bay Area, and is fluent in French, German, English and Dutch.

https://www.zylorion.com/wp-content/uploads/2022/01/Lee-Ann-e1643269535674.png

Lee-Ann Langkaas

Senior Clinical Trial Manager

Lee-Ann Langkaas

Senior Clinical Trial Manager

Lee-Ann Langkaas has over 15 years of clinical trials experience in multiple areas including Clinical Trial Management, Regulatory Compliance, Leadership, Policy,  Standard Operating Procedure Development and Quality Assurance. She also has strong financial clinical trial expertise, ensuring that each project is carried out in the most cost-effective manner. Lee-Ann has significant experience in interactions with sponsors, CROs, vendors, clinical investigators, and regulatory agencies. She has managed complex clinical trials in multiple therapeutic areas across all phases. Most recently Lee-Ann was working as a Research Manager with an internationally recognized expert group of researchers at the University of Alberta managing multiple trials from start up to close out. Lee-Ann joined Zylorion as a Senior Clinical Trials Manager and has been actively involved in the development of the clinical trials program.

https://www.zylorion.com/wp-content/uploads/2022/01/Krystal-Davidson-e1643268149686.png

Krystal Davidson

Senior Therapeutic Counsellor

Krystal Davidson

Senior Therapeutic Counsellor

Krystal Davidson has extensive experience treating patients with a wide variety of mental health conditions. This includes a large range of diverse individuals across all age ranges. She has utilized these skills in training programs both online and in-person. She was the lead therapist for a major online initiative during the COVID-19 pandemic, working alongside Dr. Silverstone, which supported over 5,000 individuals during 2020. She graduated originally from Thompson Rivers University and is a registered social worker and a certified therapist.  Krystal joined the Zylorion team at inception and has been intimately involved in her role as a Senior Therapeutic Counsellor in actively supporting development of all aspects of the Almond Therapy program, including authoring many aspects of the workbook.

https://www.zylorion.com/wp-content/uploads/2021/12/murray-weimer.png

Murray Weimer

Chairman and Director

Murray Weimer

Chairman and Director

Mr. Weimer is co-founder and Managing Director of Lightyear Capital Inc. (“Lightyear”), a privately held full-service, IIROC member, investment dealer. Mr. Weimer oversees all aspects of Lightyear’s investment banking initiatives and Lightyear’s merchant banking division. Over Mr. Weimer’s 25-year career he has supported the start up and growth of multiple companies in a diverse range of business lines and has executed on numerous M&A, valuation, equity and debt financing assignments. As Chairman of PsiloTec, Mr. Weimer is actively involved in all aspects of PsiloTec’s business strategy along with providing leadership on executing PsiloTec’s capital markets strategy. Mr. Weimer holds a Bachelor of Commerce from the University of Saskatchewan and a CPA, CA designation.

https://www.zylorion.com/wp-content/uploads/2021/12/james-mich.png

Jim Mish

Director

Jim Mish

Director

Mr. Mish is currently the CEO of 22nd Century Group, Inc., a leading plant biotechnology company focused on technologies that alter the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene editing and modern plant breeding. Mr. Mish has an outstanding 35-year track record of delivering profitable growth at both privately held and publicly traded companies with a focus on pharmaceutical and consumer products. Prior thereto, Mr. Mish served as President and CEO of Purisys, a synthetic cannabinoid API, ingredients and solutions provider to pharmaceutical and consumer products companies, and Noramco, a global leader in the production of controlled substances for the pharmaceutical industry. Mr. Mish is a graduate from the Pennsylvania State University in Chemistry and The University of Pennsylvania, Wharton School of Business.

https://www.zylorion.com/wp-content/uploads/2021/12/peter-silverstone.png

Dr. Peter Silverstone

Chief Executive Officer and Director

Dr. Peter Silverstone

Chief Executive Officer and Director

Dr. Silverstone has a 35-year background in brain and pharmaceutical research. Dr. Silverstone has highly relevant expertise in international drug and IP development, digital mental health, regulatory matters, and has been involved in multiple health related start-up companies. Dr. Silverstone previously served as the Senior Vice President, Medical and Scientific Affairs of Biovail, one of Canada’s largest publicly traded pharmaceutical companies with annual revenue in excess of a billion dollars, prior to its merger with Valeant Pharmaceutical International. Dr. Silverstone is currently the Interim Chair of the Department of Psychiatry at the University of Alberta. Dr. Silverstone received his MD at the University of London and spent three years as a research fellow at the University of Oxford. Dr. Silverstone’s research achievements have won several awards and he has published over 120 peer-reviewed articles.

https://www.zylorion.com/wp-content/uploads/2021/12/jeroen-tas-full.png

Jeroen Tas

Strategic Advisor & Board Observer

Jeroen Tas

Strategic Advisor & Board Observer

Mr. Tas is an innovation leader who applies his entrepreneurship, experience in large scale digital transformation and expertise in information technology (Cloud, AI, IoT, cyber security) to transform and grow businesses. In Mr. Tas’ 10-year tenure at Koninklijke Philips N.V. (NYSE:PHG;AMS:PHIA), in the role of Chief Innovation and Strategy Officer, Mr. Tas was instrumental in the transition of Philips to a customer-centric, digital health tech solutions company. Before joining Philips, Mr. Tas co-founded and served as President, COO and Vice-Chairman of the Board for Mphasis, a technology solutions company focused on services for the financial industry, which was acquired by HP (EDS) in 2006. Mr. Tas is the 2004 winner of the E&Y Entrepreneur of the Year Award in the Information Technology category for the New York region. Mr. Tas was also the recipient of the 2013 Dutch CIO of the year award, NASSCOM 2014 Global CIO award, the World Innovation Congress 2014 CIO Leadership award, the CIONet 2014 European CIO award, the IT Executive 2014 award, and the Accenture 2015 Innovator of the Year award. Mr. Tas is a native of the Netherlands and holds a Master’s degree in Computer Science and Business Administration from the Vrije University, Amsterdam.